'Catch-Up’ Symptoms Slow Perrigo In Cold Season

Strong cough/cold season forecast bodes well for upper respiratory and other OTCs Perrigo provides as private label and store brand products, but it isn’t expecting to capitalize in the Americas due to lingering impacts from supply chain and production disruptions linked to the COVID-19 pandemic.

• Source: Shutterstock

Perrigo Company PLC is working to catch-up on demand for its OTC cough/cold lines, likely missing $11m in revenues from the category in its latest quarter, at a time when sales are expected to jump for it and other consumer health product firms.

The firm’s doubts about delivering on projected demand for some OTCs combined with its report of a $49.4m net loss...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Supply Chain

More from HBW Insight